Browse EPCAM

Summary
SymbolEPCAM
Nameepithelial cell adhesion molecule
Aliases Ly74; TROP1; GA733-2; EGP34; EGP40; EGP-2; KSA; CD326; Ep-CAM; HEA125; KS1/4; MK-1; MH99; MOC31; 323/A3; 17- ......
Chromosomal Location2p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Lateral cell membrane Single-pass type I membrane protein Cell junction, tight junction Note=Colocalizes with CLDN7 at the lateral cell membrane and tight junction.
Domain PF00086 Thyroglobulin type-1 repeat
Function

May act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. Plays a role in embryonic stem cells proliferation and differentiation. Up-regulates the expression of FABP5, MYC and cyclins A and E.

> Gene Ontology
 
Biological Process GO:0001655 urogenital system development
GO:0001657 ureteric bud development
GO:0001822 kidney development
GO:0001823 mesonephros development
GO:0007162 negative regulation of cell adhesion
GO:0022407 regulation of cell-cell adhesion
GO:0022408 negative regulation of cell-cell adhesion
GO:0023019 signal transduction involved in regulation of gene expression
GO:0040017 positive regulation of locomotion
GO:0044331 cell-cell adhesion mediated by cadherin
GO:0048863 stem cell differentiation
GO:0051272 positive regulation of cellular component movement
GO:0072001 renal system development
GO:0072073 kidney epithelium development
GO:0072089 stem cell proliferation
GO:0072091 regulation of stem cell proliferation
GO:0072163 mesonephric epithelium development
GO:0072164 mesonephric tubule development
GO:2000047 regulation of cell-cell adhesion mediated by cadherin
GO:2000048 negative regulation of cell-cell adhesion mediated by cadherin
GO:2000147 positive regulation of cell motility
GO:2000648 positive regulation of stem cell proliferation
Molecular Function GO:0045296 cadherin binding
GO:0050839 cell adhesion molecule binding
GO:0098631 protein binding involved in cell adhesion
GO:0098632 protein binding involved in cell-cell adhesion
GO:0098641 cadherin binding involved in cell-cell adhesion
Cellular Component GO:0005923 bicellular tight junction
GO:0016323 basolateral plasma membrane
GO:0016324 apical plasma membrane
GO:0016328 lateral plasma membrane
GO:0043296 apical junction complex
GO:0045177 apical part of cell
GO:0070160 occluding junction
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-202733: Cell surface interactions at the vascular wall
R-HSA-109582: Hemostasis
Summary
SymbolEPCAM
Nameepithelial cell adhesion molecule
Aliases Ly74; TROP1; GA733-2; EGP34; EGP40; EGP-2; KSA; CD326; Ep-CAM; HEA125; KS1/4; MK-1; MH99; MOC31; 323/A3; 17- ......
Chromosomal Location2p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between EPCAM and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between EPCAM and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27697766Acute Myeloid LeukemiaInhibit immunity; immunotherapy targetIn this study, we compared gene expression patterns of acute myeloid leukemia (AML) and normal bone marrow samples and found that epithelial cell adhesion molecule (EpCAM) is frequently overexpressed in patients with AML, with EpCAM+leukemic cells exhibiting enhanced chemoresistance and oncogenesis. Finally, EpCAM antibody treatment depleted AML in subcutaneous, disseminated, and intramedullary engrafted mice. In summary, EpCAM exhibits promise as a novel target for the treatment of leukemia.
16404366Colon carcinoma; Gastric carcinoma; Prostate carcinoma; Lung carcinomaInhibit immunityFrequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.
19188665Colon CarcinomaInhibit immunity (T cell function)Here, we analyzed T-cell immune responses to the epithelial cell adhesion molecule (EpCAM), one of the most common tumor-associated antigens (TAA) serving as immune target in colon cancer patients. Th-cell priming against EpCAM inevitably resulted in interleukin-4 (IL-4)-dominated Th2 responses, even under most stringent Th1-inducing conditions. These EpCAM-reactive Th2 cells rather promoted growth of EpCAM-expressing tumors.
24980949carcinomaInhibit immunityIn conclusion, our data suggest that anti-EpCAM(scFv)-MAP may be of therapeutic value for the targeted elimination of EpCAM(+) carcinomas.
20053761Endometrial Serous AdenocarcinomaImmunotherapy targetOverexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201). EpCAM-positive cell lines were found highly sensitive to MT201-mediated antibody-dependent cellular cytotoxicity in vitro, whereas primary USPC cell lines were resistant to natural killer cell-dependent cytotoxicity.
Summary
SymbolEPCAM
Nameepithelial cell adhesion molecule
Aliases Ly74; TROP1; GA733-2; EGP34; EGP40; EGP-2; KSA; CD326; Ep-CAM; HEA125; KS1/4; MK-1; MH99; MOC31; 323/A3; 17- ......
Chromosomal Location2p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of EPCAM in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolEPCAM
Nameepithelial cell adhesion molecule
Aliases Ly74; TROP1; GA733-2; EGP34; EGP40; EGP-2; KSA; CD326; Ep-CAM; HEA125; KS1/4; MK-1; MH99; MOC31; 323/A3; 17- ......
Chromosomal Location2p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of EPCAM in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2350.627
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.1210.146
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.4190.536
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.9090.115
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.5340.745
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.3920.542
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2550.745
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.8070.478
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.3550.268
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2270.9
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.8070.757
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.260.177
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of EPCAM in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolEPCAM
Nameepithelial cell adhesion molecule
Aliases Ly74; TROP1; GA733-2; EGP34; EGP40; EGP-2; KSA; CD326; Ep-CAM; HEA125; KS1/4; MK-1; MH99; MOC31; 323/A3; 17- ......
Chromosomal Location2p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EPCAM. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolEPCAM
Nameepithelial cell adhesion molecule
Aliases Ly74; TROP1; GA733-2; EGP34; EGP40; EGP-2; KSA; CD326; Ep-CAM; HEA125; KS1/4; MK-1; MH99; MOC31; 323/A3; 17- ......
Chromosomal Location2p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EPCAM. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EPCAM.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolEPCAM
Nameepithelial cell adhesion molecule
Aliases Ly74; TROP1; GA733-2; EGP34; EGP40; EGP-2; KSA; CD326; Ep-CAM; HEA125; KS1/4; MK-1; MH99; MOC31; 323/A3; 17- ......
Chromosomal Location2p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EPCAM. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolEPCAM
Nameepithelial cell adhesion molecule
Aliases Ly74; TROP1; GA733-2; EGP34; EGP40; EGP-2; KSA; CD326; Ep-CAM; HEA125; KS1/4; MK-1; MH99; MOC31; 323/A3; 17- ......
Chromosomal Location2p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of EPCAM expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolEPCAM
Nameepithelial cell adhesion molecule
Aliases Ly74; TROP1; GA733-2; EGP34; EGP40; EGP-2; KSA; CD326; Ep-CAM; HEA125; KS1/4; MK-1; MH99; MOC31; 323/A3; 17- ......
Chromosomal Location2p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between EPCAM and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolEPCAM
Nameepithelial cell adhesion molecule
Aliases Ly74; TROP1; GA733-2; EGP34; EGP40; EGP-2; KSA; CD326; Ep-CAM; HEA125; KS1/4; MK-1; MH99; MOC31; 323/A3; 17- ......
Chromosomal Location2p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting EPCAM collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting EPCAM.
ID Name Drug Type Targets #Targets
DB05319oportuzumab monatoxBiotechEPCAM1
DB05831ING-1Small MoleculeEPCAM1
DB06607CatumaxomabBiotechCD3E, EPCAM, FCGR1A, FCGR2A, FCGR3A, FCGR3B6
DB09336Technetium Tc-99m nofetumomab merpentanSmall MoleculeEPCAM, MS4A12
DB11075HypromelloseSmall MoleculeEPCAM1